NeuroMetrix, Inc. Announces Date for Third Quarter 2022 Financial Results Conference Call

Rhea-AI Summary

NeuroMetrix (Nasdaq: NURO) will release its 2022 Q3 financial results on Oct 20, 2022, before market opening. A conference call will occur at 8:00 a.m. ET on the same day to discuss these results and other business developments. Participants can register in advance to join the call and ask questions. The company's focus is on enhancing health through innovative medical devices targeting neurological disorders. Its product line includes DPNCheck®, ADVANCE®, and Quell® Fibromyalgia, addressing various health concerns.

Positive

• Upcoming release of Q3 financial results on Oct 20, 2022.
• Scheduled conference call for in-depth discussion of results and business developments.

Negative

• None.

WOBURN, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2022 third quarter financial results before the opening of the market on Oct 20, 2022. The Company will host a conference call at 8:00 a.m., Eastern Time on Oct 20, 2022 to discuss its financial results as well as business developments affecting the Company.

For participants who wish to access the Earnings Call live via telephone and be able to ask questions, please register in advance here. Upon registering, a dial-in and unique PIN will be provided on screen and via email to join the call. An audio-only webcast of the call, along with the earnings press release and accompanying condensed financial statements, may be accessed in the Investors section of the Company’s website at www.NeuroMetrix.com. Following the conference call, a replay of the call will be available for one year on the Company's Investors section of the website.

About NeuroMetrix

NeuroMetrix is an innovation-driven company with a mission to improve individual and population health through innovative medical devices and technology solutions for neurological disorders and pain syndromes. The Company has three commercial products. DPNCheck^® is a diagnostic device that provides rapid, point-of-care detection of peripheral neuropathies. ADVANCE^® is a diagnostic device that provides automated, in-office nerve conduction studies for the evaluation of focal neuropathies. Quell^® Fibromyalgia is a wearable neuromodulator that is the first and only FDA-authorized medical device to help reduce the symptoms of fibromyalgia. For more information, visit www.NeuroMetrix.com.

NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer
neurometrix.ir@neurometrix.com

Source: NeuroMetrix, Inc.

FAQ

When will NeuroMetrix release its Q3 financial results for 2022?

NeuroMetrix plans to release its Q3 financial results on Oct 20, 2022, before the market opens.

What time is the NeuroMetrix conference call discussing Q3 results?

The NeuroMetrix conference call will take place at 8:00 a.m. ET on Oct 20, 2022.

How can I access the NeuroMetrix earnings call?

Participants can register in advance to access the NeuroMetrix earnings call and ask questions.

What products does NeuroMetrix offer?

NeuroMetrix offers DPNCheck®, ADVANCE®, and Quell® Fibromyalgia, targeting neurological disorders and pain relief.